Антифосфолипидный синдром - часть 10

чены данные о том, что у аФЛ

личение частоты носительства P1A2 аллеля

63, 64

. В других исследованиях

была установлена связь между развитием артериального тромбоза при

АФС и гомозиготным фенотипом другого тромбоцитарного гликопроте

нина GPIa/IIa (807 T/T)

65

. 

ЛИТЕРАТУРА

45

1. Albert LJ, Inman RD. Molecular mimicry

and autoimmunity. New Engl J Med 1999; 341:
2068—2074.

2. Rose NR. Infection, mimics, and autoimmune

disease. J Clin Invest 2001; 107: 943—945.

3. Wucherfenning KW. Mechanisms for the

induction of autoimmunity by infectious agents. J
Clin Invest 2001; 108: 1097—2002.

4. Merril JT. What cause the antiphospholipid

syndrome? Curr Rheum Rep 2001; 3: 293—300.

5. Gharavi AE, Wilson W, Pierangeli S. The

molecular basis of antiphospholipid syndrome.
Lupus 2003; 12: 579—583.

6. Asherson RA, Cervera R. Antiphospholipid

antibodies and infections. Ann Rheum Dis 2003;
62: 388—393.

7. Dalekos GN, Zachou K, Liaskos C. The

antiphospholipid syndrome and infection. Curr
Rheumatology Report 2001; 3: 277—285. 

8. Loizou S, Cazabon JK, Walport MJ, Tait D, So

AK. Similarities of specificity and cofactor depend
ency in serum antiphospholipid antibodies from
patients with human parvovirus B19 infection and
from those with systemic lupus erythematosus.
Arthritis Rheum 1997; 40: 103—108.

9. Gotoh M, Matsuda J. Induction of anticardi

olipin antibody and/or lupus anticoagulant in
rabbits by immunisation with lipoteichoic acid,
lipipolysaccharide and lipid A. Lupus 1996; 5:
593—597.

10. Schur PH. IgG subclasses: a review. Ann

Allergy 1987; 58: 89—100.

11. Gharavi AE, Pierangeli SS, Espinola RG, et

al. Antiphospholipid antibodies induced in mice by
immunization with a cytomegalovirus—derived
peptide cause thrombosis and activation of
endothelial cells in vitro. Arthritis Rheum 2002;
46: 545—552.

12. Labat K, Pierangeli SS, Cox T, et al. High

levels og antibodies to cytomegalovirus and to
CMVpeptide are found in sera of antiphospho
lipid syndrome patients. ACR/ARHP Annual
Acientific Meeting, Orlando, October 24—28,
2003; 326 (abst). 

13. Zhang L. Jacobsson K, Strom K, et al.

Stafylococcus aureus expresses a cell surface pro
tein that bind both IgG and beta2—glycoprotein I.
Microbiology 1999; 145: 177—183.

14. Blank M., Krause I., Fridkin M., et al.

Bacterial induction of autoantibodies to beta2—
glycoprotein 1 account for the infectious etiology of
antiphospholipid syndrome. J Clin Invest 2002;
109: 798—804.

15. Джузенова БС, Насонов ЕЛ, Ковалев

ВЮ и соавт. Антитела к кардиолипину при
острой ревматической лихорадке. Клин. ме
дицина, 1992; 2: 66—70.

16. Blank M, Sham A, Goldberg I, et. al.

"Target epitope determination for anticadiolipin
in LibmanSacks endocarditis in the antiphos
pholipid syndrome. Heart. Rheumatism and
autoimunnity February 5—7, Milan, Italy, 2004,
16 (abst).

17. Sebastiani GD, Minisola G, Galeazzi M.

HLA class II alleles and genetic predisposition to
the antiphospholipid syndrome. Autoimmune Rev
2003; 2: 387—394.

18. Hellan M, Kuhnel E, Speiser W, Lechner K,

Eichinger S. Familial lupus anticoagulant. a case
report and review of the literature. Blood Coagul
Fibrinolysis 1998; 9: 195—200.

19. May KP, West SG, Moulds J, Kotzin BL.

Different manifestations of the antiphospholipid
antibody syndrome in a family with systemic lupus
wrythematosus. Arthritis Rheum 1993; 36: 528—
533.

ГЛАВА 2. Антифосфолипидный синдром: этиология и генетическая предрасположенность

Насонов Е.Л. Антифосфолипидный синдром

46

20. Dagenais P, Urowitz MB, Gladman DD,

Norman CS. A family study of the antiphospho
lipid syndrome associated with other autoimmune
disease. J Rheumatol 1992; 19: 1393—1396.

21. McNeil HP, Gavaghan TP, Krilis SA, et al.

HLADR antigens and anticardiolipin antibodies.
Clin Exp. Rheumatol 1990; 8: 425—426.

22. Caliz R, Atsumi T, Kondeatis E, et al. HLA

class II gene polymorphism in antiphospholipid
syndrome: haplotype analysis in 83 Caucasoid
patients. Rheumatology 2001; 40: 31—36.

23. Bertolaccini ML, Atsumi T, Caliz AR, et al.

Association of antiphosphatidylserine/prothrom
bin autoantibodies with HLA class II gene.
Arthritis Rheum 2000; 43: 683—688.

24. Salvi M, Ferraccioli GF, Neri TM, et al.

HLADR antigens and anticardiolipin antibodies
in Northern Italian systemic lupus erythematosus
patients. Arthritis Rheum 1988; 31: 1568—1570.

25. McHugh NJ, Maddison PJ. HLARD anti

gens and anticardiolipin antibodies in patients
with systemic lupus erythematosus. Arthritis
Rheum 1989; 32: 1623—1624.

26. Hartung K, Coldewey R, Corvetta A, et al.

MHC gene products and anticardiolipin antibod
ies in systemic lupus erythematosus. Results of a
multicenter study. SLE study group. Autoim
munity 1992; 13: 95—99.

27. Hashimoto H, Yamanaka K, Tokano Y, et al.

HLADRB1 alleles and beta2 glycoprotein I
dependent anticardiolipin antibodies in Japanese
patients with systemic lupus erythematosus. Clin Exp
Rheumatol 1998; 16: 423—427.

28. Gulko PS, Reveille JD, Koopman WJ, et al.

Anticardiolipin antibodies in systemic lupus ery
thematosus: clinical correlates, HLA associations,
and impact survival. J Rheumatol 1993; 20:
1684—1693.

29. Sebastiani GD, Lulli P, Passiu G, et al.

Anticardiolipin antibodies: their relationship with
HLADR antigens in systemic lupus erythematoss.
Br J Rheumatol 1991; 30: 156—157.

30. Galeazzi M, Sebastiani GD, Passiu G, et al.

HLADP genotyping in patients with systemic
lupus erythematosus: correlations with autoanti
body subset. J Rheumatol 1992; 19: 42—46.

31. Galeazzi M, Sebastiani GD, Tincani A, et

al. HLA class II associations of anticardiolipin
and antibeta2 GPI antibodies in a large series of

European patients with systemic lupus erythe
matosus. Lupus 2000; 9: 47—55.

32. Arnett FC, Thiagarajan P, Ahn C, Reveille JD.

Associations of antibeta2glycoprotein I autoanti
bodies with HLA class II alleles in three etnic groups.
Arthritis Rheum 1999; 42: 268—274.

33. Wilson WA, Perez MC, Michalski JP,

Armatis P.E. Cardiolipin antibodies and null alle
les of C4 in black Americans with systemic lupus
erythematosus. J Rheumatol 1988; 15: 1768—
1772.

34. Wilson WA, Scopelitis E, Michalski JP, et

al. Familial anticardiolipin antibodies and C4
deficiency genotype that coexist with MHC DQB1
risk factors. J Rheumatol 1995; 22: 227—235.

35. Galeazzi M, Sebatiani GD, Morozzi G, et al.

HLA class II DNA typing in a large series of
European patients with systemic lupus erythe
matosus. Correlations with clinical and autoanti
body subsets. Medicine 2002; 81: 169—178.

36. Sanghera DK, Kristensen T, Hamman RF,

et al. Molecular basis of the apolipoprotein H
(beta2glycoprotein 1) polymorphism. Hum Genet
1997; 100: 57—62.

37. Koike T, Ichikawa K, Atsumi T, et al.

Epitopes on 

β

2

GPI recognized by anticardiolipin

antibodies. Lupus 1998; 7: S14—17.

38. Hirose N, Williams R, Alberts AR, et al. A

role for the polymorphism at position 247 of the
β

2

glycoprotein 1 grene and generation of anti

β

2

glycoprotein I antibodies in the antiphospho

lipid syndrome. Arthritis Rheum 1999; 42: 1655—
1651.

39. Atsumi T, Tsutsumi A, Amengual O, et al.

Correlation between 

β

2

glycoprotein I valine/

leucine 247 polymorphism and anti

β

2

glycopro

teinI antibodies in patients with primary
antiphospholipid syndrome. Rheumatology
(Oxford) 1999; 38: 721—723.

40. Prieto GA, Cabral AR, ZapataZuniga M, et

al. Valine/valine genotype at position 247 of the
beta2glycoprotein 1 gene in Mexican patients with
primary antiphosphilipid syndrome: association
with antibeta2glycoprotein1 antibodies. Arthritis
Rheum 2003; 48: 471—474.

41. De Stefano, Chiusolo P, Paciaroni K, Leone

G. Epidemiology of factor V Leiden: clinical
implications. Semin Thromb Hemost 1998; 24:
367—379. 

42. Rosendaal FR, Siscovick DS, Schwartz SM,

et al. Factor V Leiden (resistense to activated pro
tein C) increases the risk of myocardial infarction
in young women. Blood 1997; 89: 2871—2821.

43. Pablos JL, Caliz RA, Carreira PE, et al.

Risk of thrombosis in patients with antiphospho
lipid antibodies and factor V Leiden mutation. J
Rheumatol 1999; 26: 588—590.

44. Simantov R, Lo SK, Salmon JE, Sam

maritano LR, Silverstein RL. Factor V Leiden
increase risk of thrombosis in patients with
antiphospholipid syndrome. Thromb Res 1996;
84: 361—365.

45. DizonTownson D, Hutchison C, Silver R,

Branch DW, Ward K. The factor V Leiden muta
tion which predisposes to thrombosis is not common
in patients with antiphospholipid syndrome.
Thromb Haemost 1995; 74: 1029—1031.

46. Montaruli B, Borchiellini A, Tamponi G, et

al. Factor V Arg 506 Gln mutation in patients with
antiphospholipid antibodies. Lupus 1996; 5:
303—306.

47. Chopra M, Koren S., Greer WL, et al.

Factor V Leiden, prothrombin gene mutation, and
thrombosis risk in patients with antiphospholipid
antibodies. J Rheumatology 2002; 29: 1683—
1688.

48. Решетняк ТМ, Патрушев ЛИ, Стука

чева ЕА, Мирошников АИ, Тихонова ТЛ, На
сонов ЕЛ, Алекберова ЗС. Мутация Leiden,
G20210A в гене протромбина и антифосфли
пидные антитела при системной красной
волчанке и антифосфолипидном синдроме.
Терапевт. архив, 2000; 5: 34—38.

49. Dawson SJ, Hamsten A, Wiman B, et al.

Genetic vriation at the plasminogen activator
inhibitor1 locus is associated with altered levels of
plasma plasminogen activator inhibitor1 activity.
Arterioscler Thromb 1991; 11: 183—190. 

50. Mansfield MW, Stickland MH, Grant PJ.

Plasminogen activator inhibitor1 (PAI1) pro
moter polymorphism and coronary artery disease
in noninsulindependent diabetes. Thromb
Haemost 1995; 74: 1032—1034.

51. Tassies D, Espinosa G, MunozRodriguez

FJ, et al. The 4G/5G polymorohism of the type 1
plasminogen activator inhibitor gene and throm
bosis in patients with antiphospholipid syndrome.
Arthritis Rheum 2000; 43: 2349—2358.

52. Karassa FB, Bijl M, Davies KA, et al. Role

of the Fcg receptor IIA polymorphism in the
antiphospholipid syndrome. Arthritis Rheum
2003; 48: 1930—1938.

53. Arnout J. The pathogenesis of the antiphos

pholipid syndrome: a hypothrsis based on parral
lelism with heparininduced thrombocytopenia.
Thromb Haemost 1996; 75: 563—541. 

54. Kostulas K, Huang WX, Crisby M, et al. An

angiotensinconvering enzyme gene polymor
phism suggests a genetic distinction between
ischemic stroke and carotid stenosis. Eur J Clin
Invest 1999; 29: 478—483.

55. Alvarez R, Reguero JR, Batalla A, et al.

Angiotensinconverting enzyme andangiotensin II
receptor 1 polymorphisms: association with early
coronary disease. Cardiovasc Res 1998; 40:
375—379.

56. Rigat B, Hubert C, AlhenGelas F, et al. An

insertion/deletion polymorphism in the
angiotensinconverting enzyme gene account for
half the variance of serum enzyme. J Clin Invest
1990; 86: 1343—1346.

57. Danser AH, Schalekamp MA, Box WA, et

al. Angiotensinconverting enzyme in the human
heart: effect of the deletion/incertion polymor
phism. Circulation 1995; 99:340—343.

58. Butler R, Morris AD, Burchel B, Struthers

AD. DD angiotensinconverting enzyme gene
polymorphism is associated with endothelial dis
function in normal humans. Hypertension 1999;
33: 1164—1168.

59. Lewis NM, Katsumata K, Atsumi T, et al.

An evaluation of angiotensinconverting enzyme
gene polymorphism and the risk of arterial throm
bosis in patients with antiphospholipid syndrome.
Arthtitis Rheum 2000; 43: 1655—1565.

60. Weiss EJ, Bray PF, Tayback M. Polymor

phism of a platelet glycoprotein receptor as an
inheritant risk factor for coronary thrombosis. N
Engl J Med 1996; 334: 1080—1094.

61. Bray PF. Platelet glycoprotein polymor

phism as a risk factor for thrombosis. Curr Opin
Hematol 2000; 7; 284—289.

62. Byzova TV, Plow EF. The P1A2 allele and

cardiovascular disease: the pros and cos. J Clin
Invest 2000; 105: 697—698.

63. Sobel RE, Bray PF, Richardson C, Petri M,

Salmon JE. The platelet glycoprotein IIIa poly

47

ГЛАВА 2. Антифосфолипидный синдром: этиология и генетическая предрасположенность

morphism P1A2 and risk of thrombotic events in
patients with antiphospholipid antibodies Arthritis
Rheum 1998; 41 (Suppl 9): S172.

64. Tolusso B, Fabris M, Gremese E, et al.

Platelet GPIIb/IIIa (P1A1/2) polymorphism in
SLE: clinical and laboratory association. Ann
Rheum Dis 2003; 62: 781—785.

65. Font J, Tassies D, Jimenez S, et al.

Polymorphism of platelet glycoprotein Ibalpha
and Ia/II in the development of early atheroscle
rosis and arterial thrombosis in patients with
antiphoapholipid syndrome or with systemic lupus
erythematosus. ACR/ARHP Annual Scientific
Meeting 2003; October 24—28, 319 (abst).

Насонов Е.Л. Антифосфолипидный синдром

48